Oryzon to present latest advances of Vafidemstat at Oppenheimer's 29th Annual Healthcare Conference

- **Highlighting encouraging preliminary first human data in REIMAGINE Phase IIa trial**
- **Complete data on Borderline Personality Disorder (BPD) cohort will be presented at the Warsaw EPA Conference**

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, March 20th, 2019 – Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will continue its institutional presence in several reputed international investment and medical conferences in the upcoming weeks.

Dr. Carlos Buesa, Oryzon's CEO, will present its clinical programs to institutional investors at the 29th Annual Healthcare Conference being held March 19-20, 2019 at the Westin New York Grand Central in New York City. A public presentation, focused mainly on Vafidemstat, will take place on Wednesday, March 20, 2019 from 3:55 PM – 4:25 PM in the Embassy room. For more info on this event please see https://www.opco.com/conferences/healthcare19/index.aspx

Dr. Buesa will also advance encouraging topline results on Vafidemstat's REIMAGINE Phase IIa trial on a first cohort of Borderline Personality Disorder (BPD) patients. Vafidemstat was safe and well tolerated by the BPD patients, who had an overall decrease in the Columbia-Suicide Severity Rating Scale. Vafidemstat produced significant improvements in the Clinical Global Impression (CGI). Furthermore, the 4-item agitation/aggression Neuropsychiatric Inventory (NPI) subscale score and the total NPI score evidenced a statistical significant reduction after 2 months of treatment. In addition, the total BPD checklist (BPDCL), a combination of the aggression-related scores and the combination of the remaining scores (i.e. BPDCL scores not associated with aggression) all showed a statistically significant reduction as well. These preliminary data will be presented by Dr. Roger Bullock, Oryzon's Chief Medical Officer, at the 7th European Congress of Psychiatry (EPA 2019) in Warsaw (Poland) from April 6-9, 2019. For more information on this event please visit https://epa-congress.org/2019#.XID8AVVKipo

Dr. Bullock commented: "This is the first human clinical data obtained with Vafidemstat and we see a neurologically relevant effect. The fact that we have confirmed the preclinical observations from aggression models and that these observed improvements not only reduce aggressiveness but also improve the overall scales is encouraging as a proof of concept. This will be completed soon with more data from patients with other indications within REIMAGINE, giving valuable information to design further definitive studies".

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds Vafidemstat and Iadademstat in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

About Vafidemstat

Vafidemstat (ORY-2001) is an oral, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels: it reduces cognitive impairment including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies Vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease, to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, Vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has already started Phase IIa clinical studies with Vafidemstat in patients with Relapse-Remitting and Secondary Progressive MS (SATEEN), in patients with Mild to Moderate Alzheimer's disease (ETHERAL) and in aggressiveness in patients with different psychiatric or neurodegenerative disorders (REIMAGINE, a basket trial).

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon's securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

US Contact:
The Trout Group
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Idoia Revuelta
+34 91 564 07 25
pcobo@atrevia.com
irevuelta@atrevia.com

Oryzon:
Emili Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com